NEW YORK (GenomeWeb) – Quidel said today that it expects revenues in the range of $63 million to $64 million for the fourth quarter and $182 million to $183 million for full-year 2014.

The preliminary results are based on management's initial analysis of operations for the quarter ended Dec. 31, Quidel said in a filing with the US Securities and Exchange Commission.

The Q4 revenue projection would represent a 26 percent to 28 percent increase year over year. On average, analysts were estimating $57.3 million in revenues for the company in Q4.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.